만성 간질환 치료제 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 10.6%로 성장할 전망이며, 238억 3,000만 달러로 성장이 예측됩니다. 예측 기간 성장의 배경으로는 맞춤형 의료에 대한 주목 증가, 신규 치료제 파이프라인 급증, 원격의료 및 디지털 헬스 솔루션의 확대, 간질환 예방 프로그램에 대한 수요 증가, 바이러스성 간염의 이환율 증가 등이 있습니다. 주요 동향은 진단에서 인공지능의 통합, 생물학적 제제 및 유전자 치료 개발, 비침습적 치료 옵션 출현, 병용 요법 채용, 환자 중심의 케어 모델의 확대 등을 들 수 있습니다.
알코올 소비 증가는 만성 간질환 치료제 시장의 성장을 가속할 것으로 예측됩니다. 알코올 소비는 건강에 영향을 줄 수 있는 중간 정도부터 과도한 사용까지 에탄올을 포함한 음료의 섭취를 의미합니다. 알코올 소비 증가는 사회적 수용의 확대, 소득 증가, 세계 입수의 용이성 등에 기인하고 있습니다. 만성 간질환 치료제는 알코올의 과다 복용으로 인한 간 장애를 관리하고 질병 진행을 지연시키고 간 기능을 향상시키는 데 중요한 역할을 합니다. 예를 들어 2024년 6월 미국 금융기관인 퍼스트 시티즌스 은행은 2023년 DTC(Direct-to-Consumer) 와인 케이스 매출이 2022년 대비 1.2% 증가했다고 보고했습니다. 또한 2023년 12월 일본 음료회사인 기린홀딩스 주식회사가 발표한 보고서에 따르면 2022년 맥주 소비량은 약 1억 9,210만 킬로리터로 전년대비 2.9% 증가했습니다. 그 결과, 알코올 소비량 증가가 만성 간질환 치료제 시장의 확대에 기여하고 있습니다.
만성 간질환 치료제 분야의 주요 기업은 유전적 및 분자적 메커니즘에 대처하고 보다 초점을 맞춘 효과적인 치료 옵션을 제공하기 위해 RNA 요법 등의 선진적 혁신의 개발을 우선하고 있습니다. RNA 요법은 유전자 발현이나 단백질 생성을 제어하기 위해 RNA 분자를 이용하는 최첨단 의료로, 특정 유전적 메커니즘을 표적으로 함으로써 질환의 치료나 예방을 목표로 합니다. 예를 들면, 2022년 5월, 영국의 바이오 테크놀로지 기업 Ochre Bio사는, 뉴욕의 바이오파마 인큐베이터 BioLabs@NYU Langone에 '간 ICU' 조사 시설을 도입했습니다. 이 선진적인 시설에서는 관류 장치로 관리된 전체 인간 간을 이용하여 차세대 RNA 치료제의 유효성을 평가합니다. 폐기되는 기증자의 간을 연구에 이용함으로써 이 시설은 의약품 개발을 가속화하고 인간의 생리학적 조건을 재현함으로써 간 치료 연구의 정확도를 높이려 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 만성 간질환 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 만성 간질환 치료제 시장 : 성장률 분석
- 세계의 만성 간질환 치료제 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 만성 간질환 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 만성 간질환 치료제 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 만성 간질환 치료제 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항바이러스제
- 면역억제제 백신
- 면역글로불린
- 코르티코스테로이드
- 표적요법
- 화학요법
- 세계의 만성 간질환 치료제 시장 : 질환 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 간염
- 자가면역질환
- 비알코올성 지방성 간질환
- 암
- 유전성 질환
- 세계의 만성 간질환 치료제 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 만성 간질환 치료제 시장 : 항바이러스약 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 뉴클레오사이드 또는 뉴클레오티드 유사체
- 인터페론
- 직접 작용형 항바이러스약
- 세계의 만성 간질환 치료제 시장 : 면역 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 칼시뉴린 억제제
- mTOR 억제제
- 푸딩 합성 억제제
- 세계의 만성 간질환 치료제 시장 : 백신 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- A형 간염 백신
- B형 간염 백신
- 혼합 간염 백신
- 세계의 만성 간질환 치료제 시장 : 면역 글로불린 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- B형 간염 면역글로불린
- 정맥내 면역글로불린
- 세계의 만성 간질환 치료제 시장 : 코르티코스테로이드 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 프레드니솔론
- 메틸프레드니솔론
- 덱사메타손
- 세계의 만성 간질환 치료제 시장 : 표적 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 티로신 키나아제 억제제
- 단일클론항체
- 세계의 만성 간질환 치료제 시장 : 화학요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 전신 화학요법
- 동맥색전 화학요법
제7장 지역별 및 국가별 분석
- 세계의 만성 간질환 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 만성 간질환 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 만성 간질환 치료제 시장 : 경쟁 구도
- 만성 간질환 치료제 시장 : 기업 프로파일
- F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Novo Nordisk A/S
- Dr. Reddy's Laboratories Ltd.
- Vir Biotechnology Inc.
- Alnylam Pharmaceuticals Inc.
- Indian Immunologicals Limited
- Intercept Pharmaceuticals Inc.
- Viking Therapeutics Inc.
- Ascletis Pharma Inc.
- Ochre Bio Limited
- Tiziana Life Sciences Ltd.
- Antios Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 만성 간질환 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
- 만성 간질환 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
- 만성 간질환 치료제 시장(2029년) : 성장 전략
제36장 부록
AJY
Chronic liver disease therapeutics encompasses the treatments and interventions designed to manage long-term liver conditions. These therapies aim to slow disease progression, alleviate symptoms, and enhance liver function through the use of medications, lifestyle modifications, and, in some cases, advanced procedures.
The primary treatment types in chronic liver disease therapeutics include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapies, and chemotherapy. Antiviral drugs are specifically formulated to inhibit the replication of viruses in the body, aiding in the treatment and management of viral infections. These therapies address a range of conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, and genetic disorders. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.
The chronic liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides chronic liver diseases therapeutics market statistics, including the chronic liver diseases therapeutics industry global market size, regional shares, competitors with the chronic liver diseases therapeutics market share, detailed chronic liver diseases therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. This chronic liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic liver disease therapeutics market size has grown rapidly in recent years. It will grow from $14.38 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to a rise in the incidence of viral hepatitis, increasing obesity rates, an aging population, enhanced awareness of liver health, and improved patient access to treatment.
The chronic liver disease therapeutics market size is expected to see rapid growth in the next few years. It will grow to $23.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The projected growth in the forecast period can be attributed to an increased focus on personalized medicine, a burgeoning pipeline of novel therapies, the expansion of telemedicine and digital health solutions, a rising demand for liver disease prevention programs, and the increasing incidence of viral hepatitis. Major trends include the integration of artificial intelligence in diagnostics, the development of biologics and gene therapies, the emergence of non-invasive treatment options, the adoption of combination therapies, and the expansion of patient-centric care models.
The rising consumption of alcohol is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption refers to the intake of ethanol-containing beverages, ranging from moderate to excessive use, which can impact health. The increase in alcohol consumption is attributed to growing social acceptance, higher incomes, and greater accessibility worldwide. Chronic liver disease therapeutics play a crucial role in managing liver damage caused by excessive alcohol intake, slowing disease progression, and enhancing liver function. For example, in June 2024, First Citizens Bank, a US financial institution, reported a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, a report published by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase from the previous year. As a result, the rising consumption of alcohol is contributing to the expansion of the chronic liver disease therapeutics market.
Leading companies in the chronic liver disease therapeutics sector are prioritizing the development of advanced innovations, such as RNA therapies, to address genetic and molecular mechanisms, providing more targeted and effective treatment options. RNA therapies are cutting-edge medical treatments that utilize RNA molecules to regulate gene expression or protein production, with the aim of treating or preventing diseases by targeting specific genetic mechanisms. For instance, in May 2022, Ochre Bio, a UK-based biotech company, introduced its 'Liver ICU' research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This advanced facility evaluates the efficacy of next-generation RNA therapeutics using whole human livers maintained on perfusion machines. By utilizing discarded donor livers for research, the facility seeks to accelerate drug development and enhance the accuracy of liver treatment studies by replicating human physiological conditions.
In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, completed the acquisition of CymaBay Therapeutics Inc. for approximately $4.3 billion. This acquisition is intended to strengthen Gilead Sciences' portfolio in liver disease treatments, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. CymaBay Therapeutics Inc. is a US-based company dedicated to developing therapies for liver diseases, including chronic liver conditions.
Major players in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in chronic liver diseases therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the chronic liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chronic Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chronic liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chronic liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Antiviral Drugs; Immunosuppressants Vaccines; Immunoglobulins; Corticosteroids; Targeted Therapy; Chemotherapy
- 2) By Disease Type: Hepatitis; Autoimmune Diseases; Non-Alcoholic Fatty Liver Disease; Cancer; Genetic Disorders
- 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues; Interferons; Direct-Acting Antivirals
- 2) By Immunosuppressants: Calcineurin Inhibitors; mTOR Inhibitors; Purine Synthesis Inhibitors
- 3) By Vaccines: Hepatitis A Vaccine; Hepatitis B Vaccine; Combination Hepatitis Vaccines
- 4) By Immunoglobulins: Hepatitis B Immune Globulin; Intravenous Immunoglobulin
- 5) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone
- 6) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies
- 7) By Chemotherapy: Systemic Chemotherapy; Transarterial Chemoembolization Agents
- Companies Mentioned: F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Chronic Liver Diseases Therapeutics Market Characteristics
3. Chronic Liver Diseases Therapeutics Market Trends And Strategies
4. Chronic Liver Diseases Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Chronic Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Chronic Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Chronic Liver Diseases Therapeutics Market Growth Rate Analysis
- 5.4. Global Chronic Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Chronic Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Chronic Liver Diseases Therapeutics Total Addressable Market (TAM)
6. Chronic Liver Diseases Therapeutics Market Segmentation
- 6.1. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antiviral Drugs
- Immunosuppressants Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therepy
- Chemotherapy
- 6.2. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis
- Autoimmune Diseases
- Non-Alcoholic Fatty Liver Disease
- Cancer
- Genetic Disorders
- 6.3. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nucleoside Or Nucleotide Analogues
- Interferons
- Direct-Acting Antivirals
- 6.5. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Calcineurin Inhibitors
- mTOR Inhibitors
- Purine Synthesis Inhibitors
- 6.6. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Combination Hepatitis Vaccines
- 6.7. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunoglobulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hepatitis B Immune Globulin
- Intravenous Immunoglobulin
- 6.8. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prednisolone
- Methylprednisolone
- Dexamethasone
- 6.9. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tyrosine Kinase Inhibitors
- Monoclonal Antibodies
- 6.10. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Systemic Chemotherapy
- Transarterial Chemoembolization Agents
7. Chronic Liver Diseases Therapeutics Market Regional And Country Analysis
- 7.1. Global Chronic Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Chronic Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Chronic Liver Diseases Therapeutics Market
- 8.1. Asia-Pacific Chronic Liver Diseases Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Chronic Liver Diseases Therapeutics Market
- 9.1. China Chronic Liver Diseases Therapeutics Market Overview
- 9.2. China Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Chronic Liver Diseases Therapeutics Market
- 10.1. India Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Chronic Liver Diseases Therapeutics Market
- 11.1. Japan Chronic Liver Diseases Therapeutics Market Overview
- 11.2. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Chronic Liver Diseases Therapeutics Market
- 12.1. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Chronic Liver Diseases Therapeutics Market
- 13.1. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Chronic Liver Diseases Therapeutics Market
- 14.1. South Korea Chronic Liver Diseases Therapeutics Market Overview
- 14.2. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Chronic Liver Diseases Therapeutics Market
- 15.1. Western Europe Chronic Liver Diseases Therapeutics Market Overview
- 15.2. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Chronic Liver Diseases Therapeutics Market
- 16.1. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Chronic Liver Diseases Therapeutics Market
- 17.1. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Chronic Liver Diseases Therapeutics Market
- 18.1. France Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Chronic Liver Diseases Therapeutics Market
- 19.1. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Chronic Liver Diseases Therapeutics Market
- 20.1. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Chronic Liver Diseases Therapeutics Market
- 21.1. Eastern Europe Chronic Liver Diseases Therapeutics Market Overview
- 21.2. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Chronic Liver Diseases Therapeutics Market
- 22.1. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Chronic Liver Diseases Therapeutics Market
- 23.1. North America Chronic Liver Diseases Therapeutics Market Overview
- 23.2. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Chronic Liver Diseases Therapeutics Market
- 24.1. USA Chronic Liver Diseases Therapeutics Market Overview
- 24.2. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Chronic Liver Diseases Therapeutics Market
- 25.1. Canada Chronic Liver Diseases Therapeutics Market Overview
- 25.2. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Chronic Liver Diseases Therapeutics Market
- 26.1. South America Chronic Liver Diseases Therapeutics Market Overview
- 26.2. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Chronic Liver Diseases Therapeutics Market
- 27.1. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Chronic Liver Diseases Therapeutics Market
- 28.1. Middle East Chronic Liver Diseases Therapeutics Market Overview
- 28.2. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Chronic Liver Diseases Therapeutics Market
- 29.1. Africa Chronic Liver Diseases Therapeutics Market Overview
- 29.2. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Chronic Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Chronic Liver Diseases Therapeutics Market Competitive Landscape
- 30.2. Chronic Liver Diseases Therapeutics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Chronic Liver Diseases Therapeutics Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Takeda Pharmaceutical Company Limited
- 31.3. Eli Lilly and Company
- 31.4. Gilead Sciences Inc.
- 31.5. Novo Nordisk A/S
- 31.6. Dr. Reddy's Laboratories Ltd.
- 31.7. Vir Biotechnology Inc.
- 31.8. Alnylam Pharmaceuticals Inc.
- 31.9. Indian Immunologicals Limited
- 31.10. Intercept Pharmaceuticals Inc.
- 31.11. Viking Therapeutics Inc.
- 31.12. Ascletis Pharma Inc.
- 31.13. Ochre Bio Limited
- 31.14. Tiziana Life Sciences Ltd.
- 31.15. Antios Therapeutics Inc.
32. Global Chronic Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Chronic Liver Diseases Therapeutics Market
34. Recent Developments In The Chronic Liver Diseases Therapeutics Market
35. Chronic Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Chronic Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Chronic Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Chronic Liver Diseases Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
